PP_1170x120_10-25-21

Paul McMahon

Aurobindo acquires clorazepate dipotassium tablets

Aurobindo acquires clorazepate dipotassium tablets

EAST WINDSOR, N.J. – Aurobindo Pharma Limited has acquired clorazepate dipotassium tablets 3.75mg, 7.5mg and 15mg from Mylan Pharmaceuticals, a Viatris Co.. Mylan has agreed to transfer the FDA-approved ANDA for each of these products to Aurobindo Pharma USA, Inc. and Aurobindo will begin to market, distribute, and sell these products as of January 1,

Adheris Health